CD19 and diffuse large B-cell lymphoma: The US Food and Drug Administration (FDA) has approved two CD19-specific CAR-T cell therapies for B-cell malignancies in 2017: tisagenlecleucel (CTL019) for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that is refractory or has relapsed at least twice, and axicabtagene ciloleucel (KTE-C19) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).